Compare COUR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COUR | INBX |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 999.7M |
| IPO Year | 2021 | 2024 |
| Metric | COUR | INBX |
|---|---|---|
| Price | $5.46 | $102.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 3 |
| Target Price | $10.53 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 6.0M | 442.3K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $757,500,000.00 | $1,300,000.00 |
| Revenue This Year | $9.43 | N/A |
| Revenue Next Year | $6.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.04 | ★ 550.00 |
| 52 Week Low | $5.00 | $12.80 |
| 52 Week High | $13.56 | $155.29 |
| Indicator | COUR | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 45.50 |
| Support Level | $5.09 | $99.20 |
| Resistance Level | $6.41 | $153.14 |
| Average True Range (ATR) | 0.31 | 11.61 |
| MACD | -0.00 | -3.13 |
| Stochastic Oscillator | 52.16 | 7.41 |
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through two reporting segments: Consumer and Enterprise. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.